Skip to main content

New therapies for uveal melanoma

Objective

Uveal melanoma (UM) is a rare intraocular tumour with an incidence of 5 cases per million individuals per year. Up to 50% of UM patients develop metastases, most often in the liver, and these are invariably fatal. Despite new discoveries in the genetic and molecular background of the primary tumour, little is known about the metastatic disease; furthermore, there is no therapy to either prevent or treat UM metastases. In UM Cure 2020, we aim to identify and validate at the preclinical level novel therapeutic approaches for the treatment of UM metastases. For this purpose, the consortium brings together the major experts of UM in both patient care and basic/translational/clinical research, as well as patient representatives. An ambitious multidisciplinary approach is proposed to move from patient tissue characterisation to preclinical evaluation of single or combinations of drugs. This approach includes the characterisation of the genetic landscape of metastatic UM and its microenvironment, proteomic studies to address signal pathway deregulation and establishment of novel relevant in vitro and in vivo UM models. We also aim to validate accurate surrogate endpoint biomarkers to evaluate therapies and detect metastases as early as possible. Underpinning this will be the UM Cure 2020 virtual biobank registry, linking existing biobanks into a harmonised network, which will prospectively collect primary and metastatic UM samples. Together, our approach will lead to the identification of new therapies, allowing the initiation of UM-dedicated clinical trials sponsored by academia or pharma. Dissemination of results will include the building of a patient network across the countries as part of the consortium as well as a dedicated UM patient and caregiver’s data portal as part of the UM Cure 2020 website, in order to increase patient information and disease awareness.

Call for proposal

H2020-PHC-2014-2015

See other projects for this call

Sub call

H2020-PHC-2015-two-stage

Coordinator

INSTITUT CURIE
Net EU contribution
€ 1 615 871,21
Address
Rue D'ulm 26
75231 Paris
France
Activity type
Research Organisations
Non-EU contribution
€ 1 290 191,25

Participants (12)

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
Net EU contribution
€ 1 109 040,00
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 282 715,00
Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
UNIVERSITEIT LEIDEN
Netherlands
Net EU contribution
€ 434 376,25
Address
Rapenburg 70
2311 EZ Leiden
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
THE UNIVERSITY OF LIVERPOOL
United Kingdom
Net EU contribution
€ 358 604,00
Address
Brownlow Hill 765 Foundation Building
L69 7ZX Liverpool
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 214 738,50
THE UNIVERSITY OF MANCHESTER
United Kingdom
Net EU contribution
€ 993 956,00
Address
Oxford Road
M13 9PL Manchester
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,25
Region
North West (England) Greater Manchester Manchester
UNIWERSYTET JAGIELLONSKI
Poland
Net EU contribution
€ 213 792,50
Address
Ul. Golebia 24
31007 Krakow
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
Region
Makroregion południowy Małopolskie Miasto Kraków
KARLSRUHER INSTITUT FUER TECHNOLOGIE

Participation ended

Germany
Net EU contribution
€ 10 000,00
Address
Kaiserstrasse 12
76131 Karlsruhe
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
Region
Baden-Württemberg Karlsruhe Karlsruhe, Stadtkreis
FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD
Portugal
Net EU contribution
€ 248 750,00
Address
Avenida Brasilia, Centro De Investigacao Da Fundacao Champalimaud
1400-038 Lisboa
Activity type
Research Organisations
Non-EU contribution
€ 0,00
Region
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
MELANOMA PATIENT NETWORK EUROPE
Sweden
Net EU contribution
€ 61 250,00
Address
Fjallbo Selkna 152
75597 Uppsala
Activity type
Other
Non-EU contribution
€ 0,00
Region
Östra Sverige Östra Mellansverige Uppsala län
 
PAMGENE INTERNATIONAL BV
Netherlands
Net EU contribution
€ 469 625,00
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Address
Wolvenhoek 10-12
5211 HH Den Haag
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
PEP THERAPY
France
Net EU contribution
€ 97 128,79
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Address
4 Rue Pierre Fontaine Campus 3
91058 Evry
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Region
Ile-de-France Ile-de-France Essonne
 
SEEDING SCIENCE
France
Net EU contribution
€ 216 875,00
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Address
19 Rue De La Mare
75020 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Region
Ile-de-France Ile-de-France Paris
 
UNIVERSITA DEGLI STUDI DI TRENTO
Italy
Net EU contribution
€ 354 187,50
Address
Via Calepina 14
38122 Trento
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00